BTRX-335140
BTRX-335140 (also known as BTRX-140, KOR antagonist 2, or Compound 2) is a novel, orally available, and selective kappa opioid receptor (KOR) antagonist that is being developed by BlackThorn Therapeutics for the treatment of neurobehavioral disorders.
Chemistry[edit | edit source]
BTRX-335140 is a small molecule that selectively antagonizes the kappa opioid receptor. It is structurally distinct from other known KOR antagonists. The chemical structure of BTRX-335140 is represented by the following chemical formula: C22H23N5O.
Pharmacology[edit | edit source]
BTRX-335140 acts as an antagonist at the kappa opioid receptor, a type of G protein-coupled receptor (GPCR) that is activated by the endogenous opioid dynorphin. By blocking the activity of dynorphin at the KOR, BTRX-335140 is thought to alleviate symptoms associated with neurobehavioral disorders.
Clinical Development[edit | edit source]
BTRX-335140 is currently in clinical development for the treatment of neurobehavioral disorders. In preclinical studies, BTRX-335140 demonstrated a favorable safety profile and efficacy in models of depression and anxiety. The drug is currently being evaluated in Phase 2 clinical trials.
Potential Therapeutic Applications[edit | edit source]
The kappa opioid receptor has been implicated in a variety of neurobehavioral disorders, including depression, anxiety disorders, and substance use disorders. By antagonizing the KOR, BTRX-335140 may have therapeutic potential in these conditions.
See Also[edit | edit source]
References[edit | edit source]
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.Contributors: Prab R. Tumpati, MD